Profile data is unavailable for this security.
About the company
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is a China-based company primarily engaged in the business of pharmaceutical and health. The Company operates through four segments. The Great Southern Medicine segment is engaged in the research and development, manufacturing and sales of Chinese and Western patent medicines, chemical active pharmaceutical ingredients, biopharmaceuticals and natural medicines. The Great Health segment is engaged in the production, research and development and sales of beverages, food, health products and other products. The Great Commercial segment is engaged in the wholesale, retail and import and export of pharmaceutical products, medical devices, health products and other products. The Great Medical segment is engaged in the investment in medical services, traditional Chinese medicine health care, modern elderly care and medical device industries. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in CNY (TTM)77.54bn
- Net income in CNY2.99bn
- Incorporated1997
- Employees28.14k
- LocationGuangzhou Baiyunshan Pharmaceutical Holdings Co LtdNo. 45 Shamian North StreetLiwan DistrictGUANGZHOU 510130ChinaCHN
- Phone+86 2 066281218
- Fax+86 2 066281229
- Websitehttps://www.gybys.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiamen Amoytop Biotech Co Ltd | 3.34bn | 939.58m | 29.55bn | 2.42k | 31.34 | 9.79 | -- | 8.84 | 2.31 | 2.31 | 8.22 | 7.40 | 1.03 | 0.8127 | 4.99 | 1,379,284.00 | 29.05 | 22.72 | 33.93 | 26.54 | 92.37 | 91.62 | 28.11 | 23.51 | 3.20 | -- | 0.0448 | 28.80 | 34.13 | 31.02 | 49.00 | 66.70 | 41.17 | 90.06 |
| Bluestar Adisseo Co | 17.09bn | 1.19bn | 31.11bn | 2.93k | 22.71 | 1.60 | -- | 1.82 | 0.4447 | 0.4447 | 6.37 | 6.31 | 0.7204 | 5.30 | 8.18 | 5,834,541.00 | 5.03 | 5.20 | 6.05 | 6.63 | 27.69 | 29.69 | 6.99 | 8.12 | 1.12 | 10.31 | 0.1377 | 30.01 | 17.83 | 6.88 | 2,208.66 | 3.95 | 5.53 | -7.02 |
| Shanghai Junshi Biosciences Co Ltd | 2.48bn | -949.86m | 31.19bn | 2.67k | -- | 5.66 | -- | 12.56 | -0.96 | -0.96 | 2.51 | 6.05 | 0.2203 | 0.8436 | 5.48 | 963,148.80 | -9.45 | -17.61 | -12.31 | -22.00 | 81.59 | 68.46 | -42.92 | -84.56 | 1.43 | -23.04 | 0.3629 | -- | 29.67 | 20.24 | 43.90 | -- | -4.33 | -- |
| Humanwell Healthcare Group Co Ltd | 24.18bn | 1.43bn | 31.34bn | 17.65k | 21.97 | 1.66 | -- | 1.30 | 0.8741 | 0.8741 | 14.84 | 11.59 | 0.6519 | 3.63 | 2.48 | 1,369,715.00 | 5.00 | 6.40 | 8.73 | 12.55 | 44.53 | 43.83 | 7.67 | 9.90 | 1.40 | 362.14 | 0.2889 | 25.97 | 3.71 | 3.13 | -37.70 | 11.15 | 4.75 | 56.54 |
| Beijing Tiantan Biological Products Corp | 6.42bn | 1.32bn | 32.23bn | 5.30k | 24.49 | 2.81 | -- | 5.02 | 0.6656 | 0.6656 | 3.25 | 5.80 | 0.4002 | 0.9382 | 11.21 | 1,212,453.00 | 11.25 | 11.93 | 16.06 | 16.79 | 45.65 | 50.69 | 28.10 | 29.69 | 3.08 | -- | 0.0152 | 16.24 | 16.44 | 12.94 | 39.58 | 20.45 | 15.19 | 23.56 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 1.37bn | 870.39m | 36.34bn | 995.00 | 41.95 | 6.15 | -- | 26.53 | 1.40 | 1.40 | 2.21 | 9.56 | 0.186 | 1.54 | 4.55 | 1,377,045.00 | 11.66 | 3.14 | 15.35 | 3.34 | 74.88 | 77.37 | 62.65 | 16.95 | 1.97 | -- | 0.00 | 12.57 | 17.70 | 0.2733 | 139.15 | 25.17 | 16.61 | -- |
| Gan & Lee Pharmaceuticals | 3.85bn | 925.74m | 38.82bn | 5.25k | 41.45 | 3.44 | -- | 10.09 | 1.57 | 1.57 | 6.54 | 18.88 | 0.3158 | 0.9071 | 9.73 | 733,533.10 | 7.60 | 6.19 | 8.10 | 6.58 | 74.62 | 81.80 | 24.06 | 22.31 | 5.57 | -- | 0.001 | 44.12 | 16.77 | 1.02 | 80.75 | -12.04 | 1.63 | -- |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 77.54bn | 2.99bn | 39.03bn | 28.14k | 13.67 | 1.08 | -- | 0.5034 | 1.84 | 1.84 | 47.69 | 23.32 | 0.9548 | 5.79 | 4.33 | 2,755,662.00 | 3.83 | 5.33 | 7.36 | 10.95 | 16.23 | 18.07 | 4.01 | 5.28 | 1.31 | -- | 0.2873 | 28.87 | -0.692 | 2.92 | -30.09 | -2.32 | -14.01 | 6.32 |
| Beijing Tong Ren Tang Co Ltd | 18.09bn | 1.35bn | 41.97bn | 17.88k | 31.00 | 3.07 | -- | 2.32 | 0.9871 | 0.9871 | 13.19 | 9.96 | 0.5736 | 0.9376 | 11.40 | 1,011,323.00 | 5.99 | 8.13 | 11.72 | 15.95 | 43.19 | 46.02 | 10.45 | 13.34 | 1.89 | -- | 0.1629 | 33.28 | 4.12 | 6.97 | -8.54 | 9.14 | 2.30 | 5.64 |
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 20.91m | 1.49% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 13.47m | 0.96% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 9.57m | 0.68% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 8.89m | 0.63% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 8.80m | 0.63% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 4.73m | 0.34% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 4.17m | 0.30% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.15m | 0.22% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2025 | 2.23m | 0.16% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2025 | 2.11m | 0.15% |
